Drug Trial Radar · NCT00542815
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
632
Actual
Start
Nov 2007
Primary completion
Aug 2010
Study completion Aug 2010
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a PIII multi-center, open-label, flexible dose, long-term safety study, that in conjunction with the E07(NCT00416520), E08(NCT00542386) and E09(NCT00451295) studies will allow exposure to MCI-196 for up to 52 weeks
Conditions
- Chronic Kidney Disease
- Dialysis
- Hyperphosphatemia
Interventions
MCI-196Drug
3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
Another Phosphate binder (Sevelamer)Drug
Current approved dosing recommendations for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change in Serum Phosphorus for MCI-196 and SevelamerTime frame: 52 weeks (Baseline-52 weeks)
Locations
115 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Graz, Austria
Site not named
Frýdek-Místek, Czechia
Site not named
Hradec Králové, Czechia
Site not named
Ostrava, Czechia
Site not named
Prague, Czechia
Site not named
Tábor, Czechia
Site not named
Ústí nad Labem, Czechia
Site not named
Bordeaux, France
Site not named
Montpelier, France
Site not named
Paris, France
Site not named
Aschaffenburg, Germany
Site not named
Coesfeld, Germany
Site not named
Darmstadt, Germany
Site not named
Dortmund, Germany
Site not named
Düsseldorf, Germany
Site not named
Hamburg, Germany
Site not named
Homberg (Efze), Germany
Site not named
Langen, Germany
Site not named
Mannheim-Kafertal, Germany
Site not named
Ajka, Hungary
Site not named
Baja, Hungary
Site not named
Budapest, Hungary
Site not named
Esztergom, Hungary
Site not named
Győr, Hungary
Site not named
Hatvan, Hungary
Site not named
Kisvárda, Hungary
Site not named
Veszprém, Hungary
Site not named
Ancona, Italy
Site not named
Cernusco sul Naviglio, Italy
Site not named
Como, Italy
Site not named
Cremona, Italy
Site not named
Lecco, Italy
Site not named
Livorno, Italy
Site not named
Milan, Italy
Site not named
Modena, Italy
Site not named
Ostia Roma, Italy
Site not named
Pavia, Italy
Site not named
Perugia, Italy
Site not named
Rome, Italy
Site not named
Alor Star, Malaysia
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.